Stock CURE KINARUS THERAPEUTICS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kinarus Therapeutics Holding AG

Equities

CURE

CH0009115129

Market Closed - Swiss Exchange
Other stock markets
 11:30:08 2024-07-17 am EDT 		5-day change 1st Jan Change
6 CHF -10.45% Intraday chart for Kinarus Therapeutics Holding AG -7.69% +234.82%
Apr. 26 Kinarus Therapeutics Completes Merger with Unit, Rebrands as Curatis MT
Apr. 25 Curatis AG completed the acquisition of Kinarus Therapeutics Holding AG for CHF 18.3 million in a reverse merger transaction. CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 12.75 0.5241
Enterprise Value (EV) 1 14.41 0.5151
P/E ratio -0.23 x -0.01 x
Yield - -
Capitalization / Revenue 3,821,719 x -
EV / Revenue 4,318,722 x -
EV / EBITDA -45,305,833 x -133,366 x
EV / FCF 7,906,300 x -143,731 x
FCF Yield 0% -0%
Price to Book 1.91 x -1.68 x
Nbr of stocks (in thousands) 250 292
Reference price 2 51.07 1.792
Announcement Date 5/31/23 4/17/24
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales - 3.336 -
EBITDA - -0.318 -3.862
EBIT 1 -0.41 -1.84 -4.351
Operating Margin - -55.16% -
Earnings before Tax (EBT) 1 -0.143 -39.9 -50.76
Net income 1 -0.143 -34.73 -49.38
Net margin - -1,041.13% -
EPS 2 -3.912 -221.6 -176.4
Free Cash Flow - 1.822 -3.584
FCF margin - 54.62% -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 5/31/23 5/31/23 4/17/24
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 0.31 1.66 -
Net Cash position 1 - - 0.01
Leverage (Debt/EBITDA) - -5.214 x -
Free Cash Flow - 1.82 -3.58
ROE (net income / shareholders' equity) - -1,094% -1,533%
ROA (Net income/ Total Assets) - -16.2% -38.4%
Assets 1 - 214.2 128.6
Book Value Per Share 2 -10.90 26.70 -1.070
Cash Flow per Share 2 3.390 5.310 0.0300
Capex - 0 -
Capex / Sales - 0.12% -
Announcement Date 5/31/23 5/31/23 4/17/24
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. CURE Stock
  4. Financials Kinarus Therapeutics Holding AG